[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100247636":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":27,"centralContacts":31,"locations":37,"responsibleParty":55,"collaborators":23,"id":58,"slug":59,"hasResults":60,"nctId":61,"briefTitle":62,"officialTitle":62,"acronym":63,"eligibilityCriteria":64,"healthyVolunteers":60,"sex":65,"minAge":66,"maxAge":67,"enrollmentInfo":68,"targetDuration":23,"studyType":71,"phases":72,"briefSummary":74,"conditions":75,"keywords":23,"overallStatus":39,"whyStopped":23,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":86},{"fullName":5,"class":6},"Stanford University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"LDN","EXPERIMENTAL","Naltrexone HCL, 4.5 mg, Once a day.",[13],"Drug: LDN",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo","PLACEBO_COMPARATOR","Sugar pill",[19],"Drug: Placebo",[21,25],{"type":22,"name":9,"description":23,"armGroupLabels":24,"otherNames":23},"DRUG",null,[9],{"type":22,"name":15,"description":17,"armGroupLabels":26,"otherNames":23},[15],[28],{"name":29,"affiliation":5,"role":30},"Sean Mackey, MD, PhD","PRINCIPAL_INVESTIGATOR",[32],{"name":33,"role":34,"phone":35,"phoneExt":23,"email":36},"Birute Gedrimaite","CONTACT","(650) 497-0485","birute@stanford.edu",[38],{"facility":5,"status":39,"city":40,"state":41,"zip":42,"country":43,"countryCode":44,"cosmosGeoPoint":45,"geoPoint":50,"contacts":51},"RECRUITING","Palo Alto","California","94304","United States","US",{"type":46,"coordinates":47},"Point",[48,49],-122.14302,37.44188,{"lat":49,"lon":48},[52,54],{"name":33,"role":34,"phone":53,"phoneExt":23,"email":36},"650-497-0485",{"name":29,"role":30,"phone":23,"phoneExt":23,"email":23},{"type":30,"investigatorFullName":56,"investigatorTitle":57,"investigatorAffiliation":5,"oldNameTitle":23,"oldOrganization":23},"Sean Mackey","Redlich Professor Departments of Anesthesiology, Perioperative and Pain Medicine | Neurosciences | Neurology (by courtesy), Chief, Division of Pain Medicine, Director, Stanford Systems Neuroscience and Pain Lab (SNAPL), Stanford University","100247636","low-dose-naltrexone-for-the-treatment-of-complex-regional-pain-syndrome-100247636",false,"NCT02502162","Low-Dose Naltrexone for the Treatment of Complex Regional Pain Syndrome","LDN-CRPS","Inclusion Criteria:\n\n* Upper and\u002For lower extremity CRPS\n* On stable treatment for 1 month\n* CRPS for at least 1 year\n* Meet the Budapest criteria for CRPS at time of the study.\n\nExclusion Criteria:\n\n* Any known allergy to naltrexone or naloxone\n* Use of prescription opioid analgesics or illegal opioid use\n* Current or planned pregnancy.","ALL","18 Years","70 Years",{"count":69,"type":70},120,"ESTIMATED","INTERVENTIONAL",[73],"NA","The investigators are testing treatment with low-dose naltrexone (LDN) for symptom relief of complex regional pain syndrome (CRPS). Study participants will be randomly assigned to receive either LDN or placebo for a period of several weeks. During this period participants will be asked to attend either in-person or virtual study visits and complete questionnaires.",[76],"Complex Regional Pain Syndrome","2025-05-27",{"date":79,"type":80},"2025-05-29","ACTUAL",{"date":82,"type":23},"2015-06",{"date":84,"type":70},"2027-07",{"name":5,"class":6},1]